Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib
نویسندگان
چکیده
منابع مشابه
Sarcomatoid Chromophobe Renal Cell Carcinoma with Heterologous Component
Clear cellrenal cell carcinoma (RCC) is the most common malignant renal tumor in adults, while chromophobe RCC (CRCC) is the third most common. Any subtypes of RCC can undergo sarcomatoid differentiation, but heterologous differentiation in sarcomatoid area is very rare in RCC. Here a61-year male is presented with hematuria and palpable mass. Clinicoradiologically, RCC was considered and left r...
متن کاملHypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
BACKGROUND Hypertension (HTN) is an on-target effect of the vascular endothelial growth factor pathway inhibitor, sunitinib. We evaluated the association of sunitinib-induced HTN with antitumor efficacy and HTN-associated adverse events in patients with metastatic renal cell carcinoma. METHODS This retrospective analysis included pooled efficacy (n = 544) and safety (n = 4917) data from four ...
متن کاملSunitinib in patients with metastatic renal cell carcinoma.
CONTEXT Current treatment options for metastatic renal cell carcinoma (RCC) are limited and there is a need to identify novel and effective therapies. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients. OBJECTIVE To confirm the antitumor efficacy of sunitinib as second-line treatment ...
متن کاملSunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Sunitinib is a novel, multi-targeted receptor tyrosine kinase inhibitor, which has demonstrated evidence of improved survival when compared to interferon (IFN)-alpha in patients with metastatic renal cell carcinoma (RCC). Recently published National Institute for Health and Clinical Excellence guidance recommends sunitinib as a first-line treatment option for patients with advanced and/or metas...
متن کاملAlternate sunitinib schedules in patients with metastatic renal cell carcinoma.
Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor exhibiting antiangiogenic activity. Sunitinib demonstrated improved outcomes in comparison to interferon-α in a large phase III study of treatment naïve patients with metastatic renal cell carcinoma. Maintaining patients on sunitinib treatment is essential for a sustained disease control as higher exposure to sunitinib has been...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Oncologist
سال: 2016
ISSN: 1083-7159,1549-490X
DOI: 10.1634/theoncologist.2015-0428